Home>>Signaling Pathways>> Amyloid β>> Neuroscience>>(R,S)-Anatabine
(R,S)-Anatabine Catalog No.GC16032

Aβ inhibitor

Size Price Stock Qty
5mg
$36.00
In stock
10mg
$61.00
In stock
50mg
$245.00
In stock
100mg
$433.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 2743-90-0 SDF
Chemical Name 1,2,3,6-tetrahydro-2,3'-bipyridine
Canonical SMILES [C@@H]1(C2=CN=CC=C2)CC=CCN1
Formula C10H12N2 M.Wt 160.2
Solubility ≤15mg/ml in DMSO;15mg/ml in dimethyl formamide Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

Anatabine, an alkaloid with a chemical structural similarity to nicotine, is a minor tobacco alkaloid produced in plants of the Solanacea family including tobacco, green tomatoes, peppers and eggplants [1]. (R,S)-Anatabine is an Aβ inhibitor [1].

Aβ peptides play a dominant role in the development of Alzheimer's disease. Natural soluble Aβ oligomers and more specifically Aβ dimers isolated from Alzheimer's disease brains have been involved in inducing tau hyperphosphorylation and neuritic degeneration, which results in the accumulation of Aβ oligomers to the neurofibrillary degeneration observed in Alzheimer's disease [1].

In vitro: Anatabine dose-dependently lowered Aβ1-40 and Aβ1-42 levels and reduced sAPPβ production without any effects on sAPPα levels. Anatabine lowered Aβ production by mainly impacting the β-cleavage of APP. Anatabine lowered NFκB activation. Anatabine inhibited BACE-1 transcription and reduced BACE-1 protein levels in human neuronal like SHSY-5Y cells. (R,S)-Anatabine also dose dependently inhibits NF-κB activation [1].

In vivo: In a transgenic mouse model of Alzheimer's disease, acute treatment with anatabine for 4 days significantly lowered brain soluble Aβ1-40 and Aβ1-42 levels [1].

Reference:
[1] Paris D, Beaulieu-Abdelahad D, Bachmeier C, et al.  Anatabine lowers Alzheimer's Aβ production in vitro and in vivo[J]. European journal of pharmacology, 2011, 670(2): 384-391.